Developing a Novel Therapy for Parkinson's Disease

Grant number: 509286 | Funding period: 2008 - 2010

Completed

Abstract

By the time a patient first presents with symptoms of Parkinson's disease at the clinic, a large proportion (60-70%) of the cells in a specific part of the brain have been destroyed. This degeneration progresses until, within a few years, most of the cells have died. This project investigates the mechanisms involved in the continued death of cells and a possible new therapy that interrupts the progression. If the aims of this proposal are met, the drug could rapidly go to clinical trial.

Related publications (2)

l-3,4-dihydroxyphenylalanine (l-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease

JL Billings, SL Gordon, T Rawling, PA Doble, AI Bush, PA Adlard, DI Finkelstein, DJ Hare

2019-07-01

Treatment with the dopamine (DA) precursor l-3,4-dihydroxyphenylalanine (l-DOPA) provides symptomatic relief arising from DA dener..

High order W02-reactive stable oligomers of amyloid-β are produced in vivo and in vitro via dialysis and filtration of synthetic amyloid-β monomer

E Robb, K Perez, LW Hung, CL Masters, KJ Barnham, RA Cherny, AI Bush, PA Adlard, DI Finkelstein

2015-01-01

Oligomeric forms of amyloid-β (Aβ) are thought to be responsible for the pathogenesis of Alzheimer's disease. While many oligomers..

University of Melbourne Researchers

David Finkelstein